Published by Paul Wolfrom on 20. Juli 2023 Categories 2023 News Tags LimmaTech in-licenses Shigella bioconjugate vaccine from GSK to continue its clinical development; Phase I/II study completion and results are expected in 2023 Paul Wolfrom Comments are closed.